Rapid Micro Biosystems, Inc. (NASDAQ: RPID)

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company that provides automation solutions for microbial quality control in pharmaceutical manufacturing. Its flagship Growth Direct platform automates and modernizes manual microbial testing workflows, enabling faster, safer, and higher capacity drug production. The system integrates robotic sample handling, high-speed imaging, and proprietary vision algorithms to detect and count microcolonies without the need for additional reagents. By bringing the quality control laboratory to the manufacturing floor, the platform reduces turnaround time, improves data integrity, and supports compliance with regulatory standards.

The company generates revenue primarily through the sale of its Growth Direct systems, proprietary consumables, laboratory information system interface software, and related service and support contracts. After a system is installed and validated, recurring revenue is generated from ongoing consumable purchases and annual service agreements that cover maintenance, troubleshooting, and validation updates. As of the filing date, Rapid Micro Biosystems had placed approximately 190 systems worldwide and sold about nine million consumables. The company estimates the total addressable market for system sales to be around $5.0 billion and the market for annual recurring sales of consumables and services to be approximately another $5.0 billion.

Rapid Micro Biosystems positions itself as a leader in the microbial quality control market, claiming to be the first to deliver a fully automated, high-throughput solution that integrates robotic handling, advanced imaging, and data integrity features. It competes with traditional suppliers such as bioMerieux, Becton Dickinson, Charles River Labs, Merck Millipore and Thermo Fisher, as well as limited automated alternatives like Interscience, Copan Group and Clever Culture Systems. Competitive advantages include faster time-to-results (50% or quicker than manual methods), higher throughput (up to 700 samples per system), reduced manual steps, superior data integrity for compliance with regulations such as 21 CFR Part 11, and a strong patent portfolio with over 160 granted or pending patents worldwide. The company also emphasizes its first-mover advantage, deep customer collaboration, and a scalable commercial organization that supports direct sales in North America, Europe and Asia-Pacific plus a network of distributors.

The company serves a global customer base that includes approximately 107 sites across 18 countries, encompassing 75% of the twenty largest pharmaceutical companies by revenue and manufacturers of numerous FDA-approved cell and gene therapies, including 86% of approved gene-modified autologous CAR-T therapies. Specific collaborators and customers referenced in the filing include Lonza, which integrated the Growth Direct system with its MODA-EM module, and MilliporeSigma, which holds a distribution and collaboration agreement for the company's products. The majority of customers have purchased multiple systems, and over 40% have deployed Growth Direct across more than one facility location. This installed base creates a recurring revenue stream through consumables and service contracts, reinforcing long-term relationships with key pharmaceutical manufacturers.